Cargando…

A Retrospective Observational Study of Adverse Reactions Associated With Intravenous Immunoglobulin Infusion

BACKGROUND: Although intravenous immunoglobulin (IVIG) therapy is generally safe and well tolerated, adverse reactions (ARs) do occur. The majority of these ARs are mild and transient. Risk factors for ARs associate with IVIG infusions are not well established. This study investigated possible risk...

Descripción completa

Detalles Bibliográficos
Autores principales: Kato, Hidefumi, Hayashi, Megumi, Ohashi, Wataru, Yamaguchi, Takamasa, Tanaka, Satomi, Kozono, Ayumi, Gao, Siqiang, Katai, Akiko, Niwa, Reiko, Matsuo, Tomohito, Ishiyama, Kazuki, Ando, Takanori, Ogawa, Mika, Nakayama, Takayuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8479165/
https://www.ncbi.nlm.nih.gov/pubmed/34603326
http://dx.doi.org/10.3389/fimmu.2021.740517
_version_ 1784576191572738048
author Kato, Hidefumi
Hayashi, Megumi
Ohashi, Wataru
Yamaguchi, Takamasa
Tanaka, Satomi
Kozono, Ayumi
Gao, Siqiang
Katai, Akiko
Niwa, Reiko
Matsuo, Tomohito
Ishiyama, Kazuki
Ando, Takanori
Ogawa, Mika
Nakayama, Takayuki
author_facet Kato, Hidefumi
Hayashi, Megumi
Ohashi, Wataru
Yamaguchi, Takamasa
Tanaka, Satomi
Kozono, Ayumi
Gao, Siqiang
Katai, Akiko
Niwa, Reiko
Matsuo, Tomohito
Ishiyama, Kazuki
Ando, Takanori
Ogawa, Mika
Nakayama, Takayuki
author_sort Kato, Hidefumi
collection PubMed
description BACKGROUND: Although intravenous immunoglobulin (IVIG) therapy is generally safe and well tolerated, adverse reactions (ARs) do occur. The majority of these ARs are mild and transient. Risk factors for ARs associate with IVIG infusions are not well established. This study investigated possible risk factors influencing the occurrence of IVIG-associated ARs. STUDY DESIGN AND METHODS: This was a retrospective observational analysis of data accumulated over 5 years, including patient demographics, clinical condition, IVIG dosing regimens, number of IVIG infusions, and any ARs. RESULTS: ARs were associated with IVIG in 4.9% of patients and 2.5% of infusions. By univariate analyses, ARs correlated with female sex, adult age, high dose IVIG, and autoimmune disease. Multivariate logistic regression identified three statistically significant of risk factors: on a per-patient basis, being female (p=0.0018), having neuromuscular disease (p=0.0002), and receiving higher doses of IVIG per patient body weight (p<0.001), on a per-infusion basis, being female (p < 0.001), being adolescents to middle age (p < 0.001), and having neuromuscular disease (p < 0.001). CONCLUSION: Neuromuscular disease emerged as one of the significant factors for ARs to IVIG.
format Online
Article
Text
id pubmed-8479165
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-84791652021-09-30 A Retrospective Observational Study of Adverse Reactions Associated With Intravenous Immunoglobulin Infusion Kato, Hidefumi Hayashi, Megumi Ohashi, Wataru Yamaguchi, Takamasa Tanaka, Satomi Kozono, Ayumi Gao, Siqiang Katai, Akiko Niwa, Reiko Matsuo, Tomohito Ishiyama, Kazuki Ando, Takanori Ogawa, Mika Nakayama, Takayuki Front Immunol Immunology BACKGROUND: Although intravenous immunoglobulin (IVIG) therapy is generally safe and well tolerated, adverse reactions (ARs) do occur. The majority of these ARs are mild and transient. Risk factors for ARs associate with IVIG infusions are not well established. This study investigated possible risk factors influencing the occurrence of IVIG-associated ARs. STUDY DESIGN AND METHODS: This was a retrospective observational analysis of data accumulated over 5 years, including patient demographics, clinical condition, IVIG dosing regimens, number of IVIG infusions, and any ARs. RESULTS: ARs were associated with IVIG in 4.9% of patients and 2.5% of infusions. By univariate analyses, ARs correlated with female sex, adult age, high dose IVIG, and autoimmune disease. Multivariate logistic regression identified three statistically significant of risk factors: on a per-patient basis, being female (p=0.0018), having neuromuscular disease (p=0.0002), and receiving higher doses of IVIG per patient body weight (p<0.001), on a per-infusion basis, being female (p < 0.001), being adolescents to middle age (p < 0.001), and having neuromuscular disease (p < 0.001). CONCLUSION: Neuromuscular disease emerged as one of the significant factors for ARs to IVIG. Frontiers Media S.A. 2021-09-15 /pmc/articles/PMC8479165/ /pubmed/34603326 http://dx.doi.org/10.3389/fimmu.2021.740517 Text en Copyright © 2021 Kato, Hayashi, Ohashi, Yamaguchi, Tanaka, Kozono, Gao, Katai, Niwa, Matsuo, Ishiyama, Ando, Ogawa and Nakayama https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Kato, Hidefumi
Hayashi, Megumi
Ohashi, Wataru
Yamaguchi, Takamasa
Tanaka, Satomi
Kozono, Ayumi
Gao, Siqiang
Katai, Akiko
Niwa, Reiko
Matsuo, Tomohito
Ishiyama, Kazuki
Ando, Takanori
Ogawa, Mika
Nakayama, Takayuki
A Retrospective Observational Study of Adverse Reactions Associated With Intravenous Immunoglobulin Infusion
title A Retrospective Observational Study of Adverse Reactions Associated With Intravenous Immunoglobulin Infusion
title_full A Retrospective Observational Study of Adverse Reactions Associated With Intravenous Immunoglobulin Infusion
title_fullStr A Retrospective Observational Study of Adverse Reactions Associated With Intravenous Immunoglobulin Infusion
title_full_unstemmed A Retrospective Observational Study of Adverse Reactions Associated With Intravenous Immunoglobulin Infusion
title_short A Retrospective Observational Study of Adverse Reactions Associated With Intravenous Immunoglobulin Infusion
title_sort retrospective observational study of adverse reactions associated with intravenous immunoglobulin infusion
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8479165/
https://www.ncbi.nlm.nih.gov/pubmed/34603326
http://dx.doi.org/10.3389/fimmu.2021.740517
work_keys_str_mv AT katohidefumi aretrospectiveobservationalstudyofadversereactionsassociatedwithintravenousimmunoglobulininfusion
AT hayashimegumi aretrospectiveobservationalstudyofadversereactionsassociatedwithintravenousimmunoglobulininfusion
AT ohashiwataru aretrospectiveobservationalstudyofadversereactionsassociatedwithintravenousimmunoglobulininfusion
AT yamaguchitakamasa aretrospectiveobservationalstudyofadversereactionsassociatedwithintravenousimmunoglobulininfusion
AT tanakasatomi aretrospectiveobservationalstudyofadversereactionsassociatedwithintravenousimmunoglobulininfusion
AT kozonoayumi aretrospectiveobservationalstudyofadversereactionsassociatedwithintravenousimmunoglobulininfusion
AT gaosiqiang aretrospectiveobservationalstudyofadversereactionsassociatedwithintravenousimmunoglobulininfusion
AT kataiakiko aretrospectiveobservationalstudyofadversereactionsassociatedwithintravenousimmunoglobulininfusion
AT niwareiko aretrospectiveobservationalstudyofadversereactionsassociatedwithintravenousimmunoglobulininfusion
AT matsuotomohito aretrospectiveobservationalstudyofadversereactionsassociatedwithintravenousimmunoglobulininfusion
AT ishiyamakazuki aretrospectiveobservationalstudyofadversereactionsassociatedwithintravenousimmunoglobulininfusion
AT andotakanori aretrospectiveobservationalstudyofadversereactionsassociatedwithintravenousimmunoglobulininfusion
AT ogawamika aretrospectiveobservationalstudyofadversereactionsassociatedwithintravenousimmunoglobulininfusion
AT nakayamatakayuki aretrospectiveobservationalstudyofadversereactionsassociatedwithintravenousimmunoglobulininfusion
AT katohidefumi retrospectiveobservationalstudyofadversereactionsassociatedwithintravenousimmunoglobulininfusion
AT hayashimegumi retrospectiveobservationalstudyofadversereactionsassociatedwithintravenousimmunoglobulininfusion
AT ohashiwataru retrospectiveobservationalstudyofadversereactionsassociatedwithintravenousimmunoglobulininfusion
AT yamaguchitakamasa retrospectiveobservationalstudyofadversereactionsassociatedwithintravenousimmunoglobulininfusion
AT tanakasatomi retrospectiveobservationalstudyofadversereactionsassociatedwithintravenousimmunoglobulininfusion
AT kozonoayumi retrospectiveobservationalstudyofadversereactionsassociatedwithintravenousimmunoglobulininfusion
AT gaosiqiang retrospectiveobservationalstudyofadversereactionsassociatedwithintravenousimmunoglobulininfusion
AT kataiakiko retrospectiveobservationalstudyofadversereactionsassociatedwithintravenousimmunoglobulininfusion
AT niwareiko retrospectiveobservationalstudyofadversereactionsassociatedwithintravenousimmunoglobulininfusion
AT matsuotomohito retrospectiveobservationalstudyofadversereactionsassociatedwithintravenousimmunoglobulininfusion
AT ishiyamakazuki retrospectiveobservationalstudyofadversereactionsassociatedwithintravenousimmunoglobulininfusion
AT andotakanori retrospectiveobservationalstudyofadversereactionsassociatedwithintravenousimmunoglobulininfusion
AT ogawamika retrospectiveobservationalstudyofadversereactionsassociatedwithintravenousimmunoglobulininfusion
AT nakayamatakayuki retrospectiveobservationalstudyofadversereactionsassociatedwithintravenousimmunoglobulininfusion